Stock data
Kiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA) reported revenue of US$677.56M and net income of US$59.01M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$677.56M | — | US$77.22M | US$59.01M | — |
| 2024 | US$423.24M | — | -US$45.62M | -US$43.19M | — |
| 2023 | US$270.26M | — | -US$25.20M | US$14.08M | — |
| 2022 | US$220.18M | — | US$9.77M | US$183.36M | — |
| 2021 | US$38.54M | — | -US$156.64M | -US$157.92M | — |
Quarterly results
Data as of 2026-03-31
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-03-31 | US$214.27M | US$22.59M | — |
| 2025-12-31 | US$202.13M | US$14.20M | — |
| 2025-09-30 | US$180.85M | US$18.43M | — |
| 2025-06-30 | US$156.80M | US$17.83M | — |
| 2025-03-31 | US$137.78M | US$8.54M | — |
| 2024-12-31 | US$122.54M | -US$8.89M | — |
| 2024-09-30 | US$112.21M | -US$12.69M | — |
| 2024-06-30 | US$108.63M | -US$3.91M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.